NCT07813377Recruiting
Usefulness of Thromboelastography as a Predictor of Prognosis in Patients Undergoing Surgery for Glial Tumors and of the Risk of Postoperative Thromboembolic Disease (GliTEM)
Source: ClinicalTrials.gov · Last updated 10 Sept 2026
Brief summary (registry, in English)
The objective of our study is to investigate the clinical significance of thromboelastometric values in the development of thrombotic events and survival in patients with glial tumors, to reduce thromboembolic complications and optimize oncological treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 4 Sept 2026
- Start date
- 30 May 2026
- Primary completion date
- 30 May 2027
- Lead sponsor
- Fundacion Clinic per a la Recerca Biomédica
- NCT number
- NCT07813377
What you commit to
- Study type: Observational
- Planned participants: 100
- From 30 May 2026 to the primary completion date, 30 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Emergency surgery.
- Patients receiving antiplatelet or anticoagulant treatment.
Other illness
- Patients with suspected glial or neuroglial tumor in the context of long-standing epilepsy
Lab values
- Patients with known hematologic diseases associated with coagulation abnormalities. Examples include:
- Congenital or acquired platelet function disorders.
- Congenital deficiency of protein C or protein S.
- Deficiency of coagulation factors II, V, VII, X, XII.
- Glanzmann thrombasthenia.
- Hemophilia A, B, or C.
- Idiopathic thrombocytopenic purpura (ITP).
- von Willebrand disease (types I, II, and III).
- Systemic diseases that cause significant coagulation time alterations:
- Prothrombin time \< 60%.
- Activated partial thromboplastin time (aPTT) \> 50 seconds.
Age
- Patients under 18 years of age.
Who the study is looking for
- Patients undergoing surgical excision or biopsy with a diagnostic impression of glial tumor who provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Clinic Barcelona Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.